Leukemia in 100 ml PBS for 10 min at 37°C). Slides were then processed for FISH according to standard protocols with centromeric probes D7Z1 and DXZ1 (PCR generated and labelled) and 5q31-specific probe (Oncor, Illkirch, France).
Previous experiments were performed on cord blood samples ( Figure 1a ) in order to test various slide fixation and proteolytic digestion protocols, before analyzing MDS patient samples. For all three MDS patients studied, several clones could be examined. No hybridization failure was observed in unapoptotic clones. For two of the patients, interpretation of the results was complicated by either apoptosis in one case (patient 1) with poor nucleus morphology and altered DNA resulting in faint signals, or insufficient delimitation of the red cell colonies (BFU-E) for the other one (patient 2). However, in these two cases, we could draw conclusions from 11 clones for patient 1 and from 10 clones for patient 2. Patient 3 had a complex karyotype (cf Table 1 ) with several chromosome abnormalities that could be searched for by interphase cytogenetics. Two of them were selected (−7 and del(5)(q15q34)) for interphase FISH analysis. With both probes (D7Z1 and 5q31), an identical proportion of abnormal vs normal colonies was found (respectively 12 out of 15 for D7Z1 analysis and 12 out of 14 for 5q31), suggesting that both chromosome abnormalities arose early in the cell lineage development.
To determine more precisely the cell type of clones with chromosomal abnormalities, we are exploring associations of FISH with either previous MGG staining of the slides or immunocytochemical identification of the cells. 6 This technique of clonal analysis of hematopoietic stem cell cultures in MDS could be particularly useful in: (1) chromosome content analysis of clonogenic cells collected by cytapheresis from patients in remission of a leukemia to be given autologous bone marrow transplantation; (2) early detection of a relapse; (3) evaluation of the cell clonality after use of new therapeutic agents such as amifostine (Ethiol) which could favor normal vs clonal hematopoiesis. 7 In fact, this procedure can be applied to all clonal hematopoietic malignancies which display an informative karyotype in order to identify putative mosaicism between tumoral cells and normal polyclonal cells.
Finally, studies of the clonal evolution of such pathologies could bring new insights in the evolutive process of myeloproliferative disorders.
Identification of PML/RAR␣ rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients TO THE EDITOR Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17)(q22;q21) leading to the formation of PML/RAR␣ and RAR␣/PML fusion genes.
1,2 PML/RAR␣ is believed to be critical for leukemogenesis 2, 3 but the role of RAR␣/PML transcripts, which are expressed in approximately 75% of cases 4 remains to be determined. In patients with morphological APL the presence of a PML/RAR␣ rearrangement predicts a favorable response to retinoids such as ATRA, 5 which in combination with chemotherapy has been found to confer significant improvement in survival. 6 Therefore establishing the presence of a PML/RAR␣ rearrangement in suspected APL cases is valuable for optimal patient management, and for analysis of 4, 8 Absence of the t(15;17) in these cases most commonly reflects poor quality metaphases of cryptic rearrangements due to insertion events documented by molecular techniques such as RT-PCR. 3 In recent studies, fluorescence in situ hybridization (FISH) on metaphases and interphases from cytogenetic cultures has been shown to be a useful tool in identifying PML/RAR␣ in APL patients at time of diagnosis and for minimal residual disease. 9, 10 In the present study we sought to determine whether bone marrow (BM) FISH, performed directly on BM smears, using PML and RAR␣ probes could provide a more reliable indicator of the occurrence of PML/RAR␣ rearrangements than conventional cytogenetics and we compared the efficacy of this approach with RT-PCR in a series of patients drawn from the MRC ATRA trial.
The present study considers 37 patients from the trial from whom BM smears were available for FISH analysis. Cytogenetic assessment was undertaken at local centers or at the central UK MRC AML trials cytogenetic service at University College Hospital, London, according to standard methods. In each case reported to have a normal karyotype, preparations were subject to at least 18 h of culture and a minimum of 20 metaphases were examined. Nested RT-PCR for the detection of PML/RAR␣ and RAR␣/PML fusion transcripts was performed as previously described.
11 PML/RAR␣ FISH was performed as follows. For our PML/RAR␣ FISH study we used bone marrow smears received within the department at the Hammersmith Hospital from January 1993 to January 1997. In total 37 samples were analyzed of which one was a May-Grü nwald-Giemsa (MGG) stained slide, whilst the remainder were unfixed and unstained smears which had been stored at −20°C within days of receipt. Frozen BM films were allowed to warm to room temperature (RT) prior to being fixed in 3:1, methanol:acetic acid overnight at −20°C. The slides were then placed in freshly prepared 3:1 fix for 5 min, allowed to dry to RT, immersed in 70% acetic acid for 30 s and then left at RT for approximately 1 h to dry. The MGG stained slide was immersed in xylene at RT to remove the coverslip and then placed through an ethanol series. All slides were soaked in 2 × SSC at 37°C for 18-24 h, then digested with pepsin, 0.4 mg/ml in 0.01 M HCl, (Sigma-Aldrich, Dorset, UK) at 37°C for 10-15 min. They were post-fixed in 1% paraformaldehyde/phosphatebuffered saline for 10 min followed by ethanol dehydration. Slides were denatured in 70% formamide, 2 × SSC, pH 7 for 5 min at 73°C, put through an ice-cold ethanol series, then pre-heated to between 40 and 45°C prior to hybridization. The PML and RAR␣ probes (Vysis, IL, USA) were used according to the manufacturer's instructions. The slides were left to hybridize for 16-24 h at 37°C. Post-hybridization washes (3 × 5 min in 50% formamide, 2 × SSC, pH 7 and 3 × 5 mins in 2 × SSC) were performed at 42°C. Slides were mounted in Vectorshield (Vector Laboratories, Burlingame, CA, USA) containing 1 l/ml 4Ј,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). The signals were scored using an Olympus Vannox microscope equipped with a charge-coupled device camera with SmartCapture software (Digital Scientific, Cambridge, UK). Thirty-fifty nuclei were scored from each smear; the presence of two distinct green and two distinct red signals was recorded as negative, whereas nuclei containing one green, one red and a fusion signal were deemed positive. A fusion signal was defined by the presence of overlapping or touching red and green signals.
FISH using the PML and RAR␣ probes was successful in 34/37 patients (92%). In 22/34 patients in whom a result was obtained, BM FISH confirmed the presence of the PML/RAR␣ fusion (mean 90% positive nuclei, range 60-100%), whilst the remainder were considered negative (mean 3.8% nuclei positive, range 0-14%) (see Figure 1a and b) . The technique was unsuccessful in the MGG stained smear; this was attributed to difficulty in identifying FISH signals due to background staining and also to prolonged storage at RT. In the other two unsuccessful cases, hypercellularity of the smears caused difficulty in identification of signals in individual nuclei.
Of 37 cases considered in this study, 28 were confirmed as having APL (24 classical, four variant) on central morphological review (see Table 1 ). In 25 of these APL patients, material was available for RT-PCR analysis and in each case confirmed the presence of a PML/RAR␣ rearrangement. Cytogenetic analysis performed in the APL cases revealed the presence of the t(15;17) in 19/28 patients. In the remaining nine APL cases cytogenetics failed (n = 3), demonstrated a normal karyotype (n = 4) or revealed other clonal abnormalities (n = 2). BM FISH successfully identified PML/RAR␣ fusion genes in 17/19 patients with cytogenetically documented t(15;17). The technique was also positive in 4/7 patients with RT-PCR evidence of PML/RAR␣ rearrangements but lacking the t(15;17) and in one patient in whom cytogenetics failed and no material was available for further molecular analysis. In the remaining patient with morphological APL, cytogenetic analysis did not reveal the t(15;17), BM FISH was unsuccessful and no material was available for RT-PCR. PML/RAR␣ fusion genes were not detected by BM FISH in 5/26 patients with molecular and/or cytogenetic evidence for PML/RAR␣ rearrangements: the technique failed in two cases, whilst in the remaining three patients FISH analyses gave a normal signal pattern. In two of this latter group, previous FISH studies using smaller cosmid probes on washed cytospin prep- arations had demonstrated the formation of PML/RAR␣ as the sole fusion gene due to insertion events. 3 In addition, PML-staining in both of these cases showed a microparticulate nuclear staining pattern, consistent with expression of the PML/RAR␣. Absence of fusion signals with the BM FISH technique in these patients in the present study was most likely due to the relatively large size of the probes, which may be more suited to the detection of cases with PML/RAR␣ rearrangements resulting from the classical t(15;17). In nine ATRA trial patients central morphological review did not confirm the clinical diagnosis of APL. Six of these patients were found to be FAB M2 and the remaining three were classified as FAB M4. BM FISH was successful in all nine patients and in each case was negative in accordance with the morphological findings (see Table 1 and Figure 1b) , and with PML immunostaining in each of the four cases tested. In the present study we have established that BM FISH can clearly identify the presence of PML/RAR␣ rearrangements in the majority of patients with morphological APL. BM FISH has demonstrated a higher level of detection of abnormal interphases in t(15;17) patients than that observed by performing FISH on interphases obtained from cytogenetic cultures. 10 In addition, the technique successfully identified PML/RAR␣ fusion genes in a series of patients in whom conventional cytogenetics had not shown the t(15;17), due either to the presence of cryptic rearrangements or failed cytogenetics. However, in common with conventional cytogenetics, BM FISH was not invariably successful; this probably reflected the variable quality of the material available. The study suggests that the technique is most suited to the use of unstained slides kept at −20°C and also that such material should be routinely stored at the time of diagnosis in patients with suspected APL. This would then be available for FISH as well as for PML immunofluorescence studies; these have been shown to be of value for detecting the presence of PML/RAR␣ rearrangements in patients lacking the t(15;17). 3, 4 In two patients included in the present study, conventional FISH techniques using cosmid probes had previously demonstrated the formation of PML/RAR␣ fusion genes as a result of insertion events, 3 yet BM FISH was negative in both cases. These false negative results are most likely explained by the occurrence of relatively small insertions that were not readily detected by the large probes used in this present investigation, rather than by any inherent failure of the BM FISH technique per se.
In addition to its potential role in molecular diagnosis, BM FISH affords the opportunity to address more basic issues relating to the pathogenesis of APL. In combination with morphological and immunocytochemical analyses it may be possible to provide more precise information as to the hemopoietic progenitors targeted by the PML/RAR␣ rearrangement. Therefore, in conclusion we suggest that BM FISH could be used to establish the presence of PML/RAR␣ rearrangements in patients with suspected APL in whom conventional cytogenetics was either unsuccessful or uninformative and may also be of particular value in cases lacking suitable material for molecular analysis. Treatment of acute myeloid leukaemia (AML) in the elderly remains a difficult challenge and the prognosis is generally poor. This is in part due to a high frequency of adverse prognostic parameters such as karyotype and expression of multidrug resistance proteins. It is also due to the reduced ability to tolerate intensive chemotherapy. Chemotherapeutic approaches which can induce a remission with minimal toxicity are therefore of considerable potential use in these patients. We present two cases of elderly patients with AML who initially had complete remissions following treatment with low-dose melphalan but subsequently relapsed with resistant disease. At resistant relapse both had similar karyotypes with characteristic therapy-related abnormalities.
A 74-year-old female presented with red cell macrocytosis and pancytopenia in April 1997. Bone marrow biopsy showed 25% myeloblasts, trilineage dysplasia, mild hypocellularity and normal karyotype. She was initially treated with red cell transfusions 6 weekly and remained well with relatively few problems secondary to infection or bleeding. However, by January 1998 her transfusion requirements had increased to 3 weekly and we therefore commenced a trial of oral melphalan 2 mg/day. Following 2 months of treatment our patient was clinically in complete remission with a normal full blood count. This was sustained until November 1998 when a further 2-month course was administered resulting in a second remission until May 1999. A third course of melphalan at this time proved to be ineffective. At resistant second relapse her bone marrow biopsy showed 95% myeloblasts. Cytogenetic analysis and fluorescent in situ hybridisation (FISH) using whole chromosome paints for chromosomes 17 and 20 was carried out. These revealed a derivative chromosome 17 as a result of a translocation between chromosomes 17 and 20. The breakpoint on the short arm (p) of chromosome 17 was further characterised using FISH probes for the p53 and Smith Magenis (SMS) loci. p53 and SMS loci were lost confirming the breakpoint to be centromeric to SMS (17p11.2). No response was seen to subcutaneous cytarabine 20 mg twice a day for 10 days and the patient died following an intracerebral bleed in October 1999.
A 79-year-old male presented in September 1996 with red cell macrocytosis, neutropenia and thrombocytopenia. Bone marrow biopsy showed evidence of dysplasia with 8% myeloblasts and a normal karyotype. He remained well with no infective or bleeding problems and did not require red cell transfusions until June 1997. Increasing transfusion requirements led to repeat bone marrow biopsy in January 1998 and this showed 70% myeloblasts with a markedly hypocellular trephine. Cytogenetic analysis remained normal. He was treated with low-dose melphalan 2 mg/day for 2 months resulting in clinical complete remission. Falling neutrophil and platelet counts led to a repeat course of melphalan in September 1998, resulting in remission until April 1999. At this time both intravenous cytarabine 180 mg/day for 5 days and subsequently a further course of oral melpalan were inef- 1 and secondary acute myeloid leukaemia. 2 The mean total dose of melphalan required is 140 mg (70 days treatment). It is well tolerated with few infections and low transfusion requirements. Cost of treatment is also very low. Overall the complete remission (CR) rate is around 30%, but if patients with normal karyotypes or hypocellular marrows are selected the CR achieved rises to 60-75%. If CR is achieved, median survival is 27 months compared with 6.5 months in those not achieving CR. 1 Deletions of 17p are a well recognized therapy-related karyotype in MDS and AML, commonly resulting from monosomy 17, i(17q) and unbalanced translocations between chromosome 17 and other chromosomes. Partner chromosomes involved in these translocations include 5, 7, 12, 18, 21 and 22, whilst chromosome 20 is only rarely reported. 3 In a recent study of 25 cases of MDS/AML with therapyrelated 17p deletion, four patients had received prior melphalan. 4 The emergence of a t(17:20) clone in our patients coincided with clinical resistance to melphalan. Thus, whilst low-dose melphalan is a useful therapeutic option in selected elderly patients with AML, its use as a single agent may be inappropriate in younger patients.
